NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B

Cover Page

Cite item

Abstract

Аnalogues of nucleos(t)ides (AN) such as lamivudine (LAM), telbivudine (TBV), adefovir (ADP), entecavir (ENT) are widely used for the treatment of chronic hepatitis B (CHB). However, the prolonged treatment using these drugs often leads to the development of drug resistance. The most common substitutions in the reverse transcriptase are methionine for valine (rtM204V), or methionine for isoleucine (rtM204I) at position 204. Early AN-resistant mutations detection is of great importance to determine the treatment strategy of patients with CHB. Currently there are many highly sensitive methods for detection of drug resistance mutations, such as next-generation sequencing, reverse hybridizationbased line probe assay (LiPA), mass spectrometry. However, these methods require expensive equipment and reagents, and they are not widely used in clinical laboratories. The aim of this study was to develop a simple and accurate real-time PCR method for detection of rtM204I/V mutation. This method showed high specificity and sensitivity (1000 copies/ml), it is less laborious and does not require additional equipment, fast and cost effective compared to other methods. HBV mutations of resistance to AN were determined in 5 groups of patients with CHB. Patients of the first group received monotherapy with pegylated interferon (n = 12), the second group — lamivudine (n = 10), the third group — telbivudine (n = 7), the fourth group — entecavir (n = 15). The fifth group consisted of patients who did not receive antiviral therapy (n = 3). The frequency of mutations in HBV polymerase YMDD-motif was determined among 47 patients with CHB: it was 10% for lamivudine treated patients, 20% — for entecavir, 28% — for telbivudine. YIDD/YVDD motifs were identified in two patients and YMDD/YIDD — in one patient. Real-time PCR method for the detection of AN-resistant rtM204I/V mutations in HBV polymerase can be used in routine diagnostics for primary screening of patients not responding to AN treatment. The application of this method can reduce the number of samples for in-depth study of primary and compensatory mutations of resistance to AN by sequencing method. The developed method versus Sanger-sequencing is fast, economical, and provides the detection of minor variants of HBV populations. 

About the authors

E. A. Elpaeva

Research Institute of Influenza, St. Petersburg, Russian Federation

Author for correspondence.
Email: fake@neicon.ru

Researcher of the Laboratory of Molecular Virology and Genetic Engineering, Research Institute of Influenza, St. Petersburg, Russian Federation;

Russian Federation

A. B. Komissarov

Research Institute of Influenza, St. Petersburg, Russian Federation

Email: fake@neicon.ru

Senior Researcher of the Laboratory of Molecular Virology and Genetic Engineering, Research Institute of Influenza, St. Petersburg, Russian Federation; 

Russian Federation

M. M. Pisareva

Research Institute of Influenza, St. Petersburg, Russian Federation

Email: fake@neicon.ru

PhD (Biology), Leading Researcher of the Laboratory of Molecular Virology and Genetic Engineering, Research Institute of Influenza, St. Petersburg, Russian Federation; 

Russian Federation

M. P. Grudinin

Research Institute of Influenza, St. Petersburg, Russian Federation

Email: fake@neicon.ru

PhD (Biology), Head of the Laboratory of Molecular Virology and Genetic Engineering, Deputy Director for Research and Development, Research Institute of Influenza, St. Petersburg, Russian Federation; 

Russian Federation

O. I. Kiselev

Research Institute of Influenza, St. Petersburg, Russian Federation

Email: fake@neicon.ru

PhD, MD (Biology), Professor, Academician of the Russian Academy of Sciences, Director of the Research Institute of Influenza, St. Petersburg, Russian Federation

Russian Federation

References

  1. Елпаева Е.А., Порецкова Е.А., Ковеленов А.Ю., Аликян И.С., Гальбрайх Р.Б., Грудинин М.П., Эсауленко Е.В. Генотипическая характеристика вируса гепатита В у хронически инфицированных больных // Дальневосточный журнал инфекционной патологии. 2009. № 15. С. 56–59. [Elpaeva E.A., Poretskova E.A., Kovelenov A.Yu., Alikyan J.S., Galbraikh R.B., Grudinin M.P., Esaulenko E.V. Genotypic characterization of the hepatitis B virus in chronically infected patients. Dal’nevostochnyi zhurnal infektsionnoi patologii = Far Eastern Journal of Infection Pathology, 2009, no. 15, pp. 56–59. (In Russ.)]
  2. Елпаева Е.А., Писарева М.М., Никитина О.Е., Кижло С.Н., Грудинин М.П., Дуданова О.П. Роль мутантных форм вируса гепатита B в прогрессирующем течении хронического гепатита В // Ученые записки Петрозаводского государственного университета. Естественные и технические науки. 2014. Т. 143, № 6. С. 41–46. [Elpaeva E.A., Pisareva M.M., Nikitina O.E., Kizhlo S.N., Grudinin M.P., Dudanova O.P. The role of the mutant forms of hepatitis B virus in the progressive course of chronic hepatitis B. Uchenye zapiski Petrozavodskogo gosudarstvennogo universiteta. Estestvennye i tekhnicheskie nauki = Scientific Notes of Petrozavodsk State University. Natural and Engineering Sciences, 2014, vol. 143, no. 6, pp. 41–46. (In Russ.)]
  3. Dandri M., Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut, 2012, vol. 61, no. 1, pp. 6–17. doi: 10.1136/gutjnl-2012-302056
  4. Feng Z.L., Yu X.Y., Lu Z.M., Geng D.Y., Zhang L., Chen S.J. Rapid detection of the hepatitis B virus YMDD mutant using AllGlo™ probes. Clin. Chim. Acta., 2011, vol. 412, iss. 11–12, pp. 1018–1021. doi: 10.1016/j.cca.2011.02.012
  5. Gao S. Clinical relevance of hepatitis B virus variants. World J. Hepatol., 2015, vol. 7, no. 8, pp. 1086–1096. doi: 10.4254/wjh.v7.i8.1086
  6. Hua W., Zhang G., Guo S., Li W., Sun L., Xiang G. Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection Brazilian. J. Infect. Dis., 2015, vol. 19, no. 3, pp. 291–295. doi: 10.1016/j.bjid.2015.03.012
  7. Ko S.-Y., Oh H.-B., Park C.-W., Lee H.C., Lee J.-E. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. Clin. Microbiol. Infect., 2012, vol. 18, no. 10, pp. 404–411. doi: 10.1111/j.1469-0691.2012.03951.x
  8. Lin C.-L., Kao J.-H. Hepatitis B virus genotypes and variants. Cold Spring Harb. Perspect. Med., 2015, vol. 5, no. 5, pp. a021436–a021436. doi: 10.1101/cshperspect.a021436
  9. Locarnini S., Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir. Ther., 2010, vol. 15, no. 3, pp. 451–461. doi: 10.3851/IMP1499
  10. Locarnini S., Zoulim F. Molecular genetics of HBV infection. Antivir. Ther., 2010, vol. 15, no. 3, pp. 3–14. doi: 10.3851/IMP1619
  11. Niesters H.G.M., Zoulim F., Pichoud C., Buti M., Shapiro F., D’Heuvaert N., Celis L., Doutreloigne J., Sablon E. Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob. Agents Chemother., 2010, vol. 54, no. 3, pp. 1283–1289. doi: 10.1128/AAC.00970-09
  12. Rybicka M., Stalke P., Dreczewski M., Smiatacz T., Bielawski K.P. High-throughput matrix-assisted laser desorption ionizationtime of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus. J. Clin. Microbiol, 2014, vol. 52, no. 1, pp. 9–14. doi: 10.1128/JCM.01891-13
  13. Shi M., Yang Z.J., Wang R.S., Zhang H., Zhu Y.F., Xu Y.P., Lin Q.Y., Jin L.J. Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection. Clin. Chim. Acta., 2006, vol. 373, iss. 1–2, pp. 172–175. doi: 10.1016/j.cca.2006.05.023
  14. Stuyver L.J., Locarnini S.A., Lok A., Richman D.D., Carman W.F., Dienstag J.L., Schinazi R.F. Nomenclature for antiviralresistant human hepatitis B virus mutations in the polymerase region. Hepatology, 2001, vol. 33, no. 3, pp. 751–757. doi: 10.1053/jhep.2001.22166
  15. Wang R.S., Zhang H., Zhu Y.F., Han B., Yang Z.J. Detection of YMDD mutants using universal template real-time PCR. World J. Gastroenterol., 2006, vol. 12, no. 8, pp. 1308–1311. doi: 10.3748/wjg.v12.i8.1308

Copyright (c) 2015 Elpaeva E.A., Komissarov A.B., Pisareva M.M., Grudinin M.P., Kiselev O.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies